Teoxane 提出收购 Revance Therapeutics 的优越方案

Reuters
Jan 06, 2025

((自动化翻译由路透提供,请见免责声明 ))

路透1月6日 - Teoxane SA提出的收购Revance Therapeutics 的价格高于上个月Crown Laboratories提出的收购要约。

Teoxane的提议比12月9日Revance与Crown Laboratories达成的合并 (link),每股3.10美元的价格溢价16%。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10